文献速递肿瘤 PET/CT

前列腺癌PSMA阳性复发罕见部位:隐睾内孤立性转移

Unusual Site of Solitary PSMA-Positive Recurrence of Prostate Cancer in an Undescended Testis.
PubMed 文献 · Clin Nucl Med · 2026-04-02

本文报道一例前列腺癌生化复发患者在[¹⁸F]-Piflufolastat PSMA PET/CT上发现隐睾内孤立性转移灶。生化复发发生于约20%-40%的前列腺癌患者,PSMA-PET/CT在低PSA水平检测复发和转移优于传统影像。该病例凸显先进分子影像在识别非典型转移、影响临床决策中的关键作用。

要点

  • 前列腺癌生化复发率约20%-40%,是临床重要挑战。
  • PSMA-PET/CT在低PSA水平检测复发转移优于传统影像。
  • 隐睾内孤立性PSMA阳性转移属非典型部位,可影响临床决策。

核心结论

  • PSMA-PET/CT可识别前列腺癌隐睾内孤立性非典型转移灶,对临床决策有直接影响。

研究设计与样本

  • 单病例报告,描述一例PSA升高的前列腺癌患者在[¹⁸F]-Piflufolastat PSMA PET/CT上发现隐睾内转移。

主要发现

  • 该患者在隐睾内检出孤立性PSMA阳性复发灶,属不常见转移部位。
  • 生化复发发生于约20%-40%的前列腺癌患者。
  • PSMA-PET/CT在低PSA水平检测复发和转移优于传统影像。

临床怎么用

  • 对PSA升高的前列腺癌生化复发患者,PSMA-PET/CT有助于发现包括隐睾在内的非典型转移部位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer is the most frequently diagnosed malignancy among men. Biochemical recurrence occurs in ∼20%-40% of patients and poses a significant clinical challenge. PSMA-PET/CT has emerged as a highly sensitive and specific imaging modality for detecting recurrent and metastatic prostate cancer, outperforming conventional imaging, especially at low PSA levels. We report an unusual site of metastatic recurrence detected on [¹⁸F]-Piflufolastat PSMA PET/CT in a patient with rising PSA. This case highlights the crucial role of advanced molecular imaging in accurately identifying atypical metastatic spread, which may have a direct impact on clinical decision-making.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pinaquy JB, Bonichon-Lamichhane N, Lopez L, et al. Unusual Site of Solitary PSMA-Positive Recurrence of Prostate Cancer in an Undescended Testis. Clin Nucl Med. 2026. PMID: 41954950. doi:10.1097/RLU.0000000000006470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。